The patients underwent CABG who met the study criteria in our hospital were included. According to the types of postoperatively administered statin drugs， the patients were divided into rosuvastatin group and simvastatin group， and there were 150 cases in each group. The baseline characteristics of patients and theirs blood lipid status at admission and 1 year after CABG were recorded. The occurrence of major adverse cardiovascular events （MACE） such as cardiovascular death and recurrent angina， as well as safety-related adverse events such as abnormal liver function and myopathy were noted. Meanwhile coronary computed tomography angiography（CTA） was performed 1 year after operation， and its stenosis index was calculated.

A total of 286 cases were followed up， with a follow-up rate of 95.3%， including 140 cases in rosuvastatin group and 146 cases in simvastatin group. In terms of blood lipid changes， compared with before operation， the total cholestrol（TC） and low density lipoprotein-cholesterol（LDL-C） levels in rosuvastatin grouop and simvastatin group 1 year after operation were significantly decreased （P<0.05），and the levels of high density lipoprotein-cholesterol（HDL-C） were significantly increased（P<0.05）. In terms of MACE and safety events， there were no statistically significant differences between two groups （P>0.05）. The stenosis indexes of the patients in rosuvastatin group and simvastatin group were 4.55（0 —11.86） vs 5.78（0 —13.00）， and the difference was not statistically significant （P>0.05）.

Moderate dose of rosuvastatin and simvastatin can make the serum LDL-C level meet the standard of lipid lowering. There is no difference in the efficacies or safeties between two kinds of drugs， and both drugs could be used as secondary prevention strategies after CABG in the Chinese patients with coronary heart disease.